US FDA approves Roche's Enspryng for thyroid eye disease, offering first at-home subcutaneous treatment.

The U.S. Food and Drug Administration (FDA) has approved Enspryng (satralizumab) for the treatment of adults with thyroid eye disease (TED). This marks the first and only at-home subcutaneous treatment option for the condition, allowing administration by patients or caregivers after appropriate training. The approval is supported by data from the pivotal Phase III SatraGO program.